Cullinan Therapeutics starts registrational Phase 2 trial for CLN-049
Cullinan Therapeutics dosed the first patient in a potentially registrational Phase 2 single-arm study of CLN-049 for relapsed/refractory AML.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.